Inhibition of mutated BRAF in melanoma.
Taegyun
T
Kim
Jihyun
J
Kim
Min-Geol
MG
Lee
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D019008:Drug Resistance, Neoplasm; D011905:Genes, ras; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D007546:Isoquinolines; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D009154:Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics*; D013449:Sulfonamides / Q000008:administration & dosage*; D000077484:Vemurafenib
C507022:1-isoquinolyl-(3-(trifluoromethyl)phenyl)methanone; D000970:Antineoplastic Agents; D007211:Indoles; D007546:Isoquinolines; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D020928:Mitogen-Activated Protein Kinases